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Abstract 
Studies have shown that moderate alcohol consumption is strongly associated with reduced reporting 
of chronic widespread pain (CWP). The study designs used however are prone to confounding and are 
not able to establish the direction of causality. The current study overcomes these problems by using 
the Mendelian randomisation design to determine the effect of alcohol consumption on the likelihood 
of reporting CWP. The UK Biobank recruited 500,000 participants aged between 40 and 69 years. Data 
collected included questions on chronic pain and alcohol consumption, and biological samples 
providing genotypic information. Alcohol consumption was categorised as ‘weekly consumption’ or 
‘non or infrequent’. Participants were classified by genotype according to alleles of the rs1229984 
SNP, either ‘GG’ or ‘AA/AG’. CWP was defined as pain all over the body for more than 3 months that 
interfered with activities. Associations between genotype, CWP and alcohol consumption were tested 
by logistic regression. Instrumental variable analysis was used to calculate the causal effect of weekly 
alcohol consumption on CWP. Persons with ‘GG’ genotype had an increased risk of CWP (odds ratio, 
OR 1.17, 99% confidence interval CI 1.01-1.35) and were more likely to consume alcohol weekly (OR 
1.76, 1.70-1.81) compared to those with ‘AA/AG’ genotype. Weekly consumption of alcohol was 
associated with reduced risk of CWP (OR 0.33, 0.31-0.35), but instrumental variable analysis did not 
show a causal effect of alcohol consumption on reducing CWP (OR 1.29, 0.96-1.74). An interpretation 
of observational population studies as showing a protective effect of alcohol on CWP is not supported. 
Keywords: alcohol, drinking, chronic widespread pain, epidemiology, Mendelian randomisation  
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INTRODUCTION 
A defining feature of fibromyalgia is chronic pain all over the body, or chronic widespread pain (CWP) 
[23,24]. One estimate of global fibromyalgia prevalence is 2.7% [20] but estimates can range from 1.1 
to 6.4% depending on criteria used [11,22]. Meta-analyses have estimated CWP prevalence at 9.8% 
globally [1] and 14.2% within the UK [7]. Among lifestyle factors associated with fibromyalgia and CWP 
is alcohol consumption. One study among fibromyalgia patients found moderate alcohol consumption 
was associated with reduced symptom severity compared to abstention [13]. The authors suggested 
ethanol-enhanced production of γ-Aminobutyric Acid (GABA) [12] as a mechanism for effects of 
alcohol in people with fibromyalgia, among whom studies have shown decreased levels of GABA [9]. 
Population studies have found CWP is less common among persons with moderate alcohol 
consumption, even among those who had not reduced drinking due to ill health [3]. In one study, 
those drinking 11 to 35 units a week were a third less likely to report CWP as those who had never 
drunk regularly, while among people with CWP, moderate alcohol consumption was associated with 
less disability [15]. 
There are limits to inferences that can be drawn from observational studies [8]. It is conceivable that 
alcohol has analgesic effects, and that is why moderate drinkers report less pain. However, these 
studies are prone to confounding and ‘reverse causation’. A confounded relationship would mean a 
third variable associated with alcohol consumption but is not its consequent, though it may be its 
antecedent, has an effect on pain.  ‘Reverse causation’ could mean that people reduce their alcohol 
intake because they have chronic pain. Both explanations would produce the associations described 
in previous studies.  
One study design that overcomes some of these problems is Mendelian randomisation [2]. Mendelian 
randomisation is particularly useful when a randomised trial is not feasible, as when studying effects 
of alcohol consumption. In this design, genetic variants strongly associated with a particular 
behaviour, such as a single genetic base or single-nucleotide polymorphism (SNP), are chosen as proxy 
measures for the behaviour [14]. Their distribution throughout a population is assumed random, so 
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their influence is assumed to be distributed randomly and not influenced by confounders. One SNP 
that affects alcohol consumption is rs1229984 on chromosome 4, in the gene ADH1B for alcohol 
dehydrogenase. The common variant of this SNP is the guanine (G) nucleotide, while a smaller number 
of people carry one or two copies of the adenine (A) allele (global minor allele frequency between 
0.0628 and 0.159 [19]). Among people with the rare variant, increased production of alcohol 
dehydrogenase converts ethanol to acetaldehyde more rapidly so unpleasant effects are experienced 
after consuming alcohol [4]. Because of ill effects of alcohol, people manifesting AA or AG at rs1229984 
consume less. 
The current analysis aimed to examine the association of variants of the rs1229984 SNP with reporting 
of CWP in a large population sample from the UK, and to use the variants as an instrumental variable 
for estimating the causal effect of alcohol consumption on CWP.  
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METHODS 
UK Biobank 
The UK Biobank recruited over 500,000 participants aged between 40 and 69 years from among 
patients registered at general medical practitioners within the UK National Health Service [21]. Around 
9.2 million people were invited to take part in the study, making a participation rate of 5.5% [16]. 
Participants attended assessment centres across the UK where they completed by touchscreen 
electronic questionnaires that included questions on health and lifestyle. Physical measures and 
biological samples were also collected at assessment centre visits. The UK Biobank is overseen by the 
UK Biobank Ethics and Governance Council, and has received approval from appropriate ethics 
committees. 
Pain questions 
Participants were asked by touchscreen questionnaire ‘In the last month have you experienced any of 
the following that interfered with your usual activities?’ They were provided with a list of  options to 
choose from: headache, facial pain, neck or shoulder pain, back pain, stomach or abdominal pain, hip 
pain, knee pain, pain all over the body, none of the above, prefer not to answer. Participants who 
chose ‘pain all over the body’ were not offered the option of choosing any other pain sites. For each 
pain selected or for ‘pain all over the body’, they were then asked if they had the pain for more than 
3 months. Participants were classified as having CWP if they answered they had ‘pain all over the 
body’, and that they had experienced this for more than 3 months. This definition of CWP has been 
used in a number of previous studies [3,16,17] 
Alcohol questions 
Participants were also asked ‘About how often do you drink alcohol?’, and given a number of options 
from which to choose. If participants answered ‘once or twice a month’, ‘special occasions only’, or 
‘never’ they were classified as ‘non or infrequent’ drinkers of alcohol for this analysis. If their answer 
was ‘once or twice a week’, ‘3 or 4 times a week’, or ‘daily’, they were classed as ‘weekly consumers’ 
of alcohol.  
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Other chronic pain risk markers 
A number of other risk markers for CWP were collected at the assessment centre visit and used as 
adjusting factors: age at time of visit in whole number of years, BMI calculated from height and weight 
measured at visit, and Townsend Deprivation index derived from a participant’s postcode. The 
following were also collected by touchscreen questionnaire: employment (classified for this analysis 
as employed/self-employed, retired, unable to work because of sickness/disability, unemployed, or 
none of the above/other); smoking (never, tried once or twice, previous occasional smoker, previous 
smoking most days, current occasional smoker, or current smoker most days); self-reported ethnic 
group (classed as white or non-white ethnic background for this analysis); university degree or not; 
measures of mood (ever felt miserable, often felt fed-up); and frequency of visits with friends and 
family (2 or more a week versus 1 or less). 
Genotyping information 
Genotyping information was available for UK Biobank participants. Variants of rs1229984 were used 
as markers for exposure to alcohol consumption. This SNP lies in exon 3 of the ADH1B gene which 
codes for an alcohol dehydrogenase. The reference allele is guanine (G) and carriers of one or two 
copies of the adenine (A) allele have faster metabolism of alcohol. These people are more likely to 
have unpleasant effects from drinking and so drink less and are at lower risk for alcoholism [4]. For 
this analysis, participants were classed as either carrying the ‘GG’ or ‘AA/AG’ variants of rs1229984. 
Those with ‘AA’ and ‘AG’ variants were combined into one group because of the lower minor allele 
frequency for rs1229984 [4].  
Analysis 
Stata/SE 13.0 was used to examine associations between alcohol consumption, CWP, and genotype. 
First, the association between reporting CWP and variants of the rs1229984 SNP was examined. The 
percentage of those having CWP in each genotype (‘AA/AG’ and ‘GG’) was calculated. Logistic 
regression was used to calculate the odds ratio (OR) with 99% confidence interval (CI) for reporting 
CWP in those with the ‘GG’ genotype compared to those with ‘AA/AG’. Analyses were performed 
7 
 
separately for males and females, and in those of self-reported white and non-white ethnicity. 
Analyses were stratified by gender and ethnicity since gender is associated with both CWP and alcohol 
consumption, and self-reported ethnicity is associated with CWP and genotype. ORs adjusted for age, 
gender, and chronic pain risk markers, were calculated 
In order to confirm the association of the rs1229984 SNP with alcohol consumption, the proportion of 
weekly consumers of alcohol and those not consuming or consuming infrequently was calculated for 
each genotype. Logistic regression was used to calculate ORs of weekly consumption of alcohol in 
those with the ‘GG’ genotype compared to those with ‘AA/AG’. This was repeated separately for those 
of each gender, and for those of self-reported white and non-white ethnicity. 
Next, the association between alcohol consumption and CWP in the population was confirmed. The 
percentage of those with CWP in consuming alcohol weekly, and in those not consuming or consuming 
infrequently was calculated. ORs for reporting of CWP in ‘weekly consumers’ compared to ‘non or 
infrequent’ consumers were calculated with 99% confidence intervals (CI) by logistic regression. 
Adjusted odds ratios (AORs) with 99% CIs were then calculated using logistic regression. Analyses were 
repeated in those of white and non-white ethnicity, and in both genders. 
Instrumental variable analysis by the inverse-variance weighting (ratio) method [5] was used to 
calculate the causal effect of weekly consumption of alcohol on CWP, using variants of the rs1229984 
SNP as an instrumental variable and ‘non or infrequent’ as the reference category. In this method, the 
ratio of the coefficient of CWP regressed on genotype (adjusted for covariates) to the coefficient of 
alcohol regressed on genotype (also adjusted) gives the causal estimate of the effect of alcohol on 
CWP. The coefficients were obtained from logistic regression models, and odds ratios were obtained 
by exponentiation of the ratio of the coefficients. The standard error estimates for the risk ratios were 
adjusted for the observed correlation between CWP and alcohol consumption.  ORs with 99% CIs are 
reported overall and separately for each category of gender and ethnicity.  
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RESULTS 
Alcohol consumption information was available for 501,098 participants of whom 344,656 (68.9%) 
reported consuming alcohol weekly. Pain information was available for 500,410 participants of whom 
7,130 (1.4%) reported CWP. Genotype was available for 486,321 participants of whom 28,511 (5.9%) 
were ‘AA/AG’. The number of participants who had alcohol, pain, and genotype information available 
was 484,178. Characteristics of participants by genotype are given in Table 1. Those with ‘GG’ 
genotype tended to have higher BMI and greater deprivation than those of ‘AA/AG’ genotype, and 
were less likely to be of non-white ethnicity. There were also differences in employment status and 
number of those with a university degree. Differences in smoking behaviour and other characteristics 
were small. 
Genotype and CWP 
Participants of ‘GG’ genotype were slightly more likely to report CWP than those with ‘AA/GG’ (Table 
2) (1.4 vs. 1.2%, OR 1.17, 99% CI 1.01-1.35)). The estimate of effect did not exclude the null in the 99% 
CI after adjustment for other risk markers (aOR 1.14, 0.97-1.33). Higher prevalence of CWP was also 
seen among those with the ‘GG’ genotype when looking separately at those of white ethnicity and 
non-white ethnicity (1.3 vs. 1.1%, OR 1.25, 1.06-1.48, and 3.4 vs. 2.1%, OR 1.64, 1.24-2.20 
respectively). The size of these effects were attenuated and failed to exclude the null from the 99% CI 
when adjusted for CWP risk markers. 
Genotype and alcohol consumption 
Among participants for whom information on alcohol consumption and genotype was available, there 
were differences in alcohol consumption among those of the ‘GG’ and ‘AA/AG’ genotypes (Table 3). 
Among males, those of ‘GG’ genotype were more likely to consume alcohol weekly compared to those 
with ‘AA/AG’ (77.8 vs. 67.1%, OR 1.71, 1.63-1.80, aOR 1.60, 1.52-1.69). Among females the same 
patterns were observed with 62.9% of those of ‘GG’ genotype consuming alcohol weekly compared 
to 47.8% of those drinking none or infrequently (OR 1.85, 1.77-1.93, aOR 1.77, 1.69-1.86). The same 
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pattern was observed in both those of white and non-white ethnicities, with a greater proportion 
among those of ‘GG’ genotype consuming alcohol weekly. 
Association between alcohol consumption and CWP in the population 
Participants who reported consuming alcohol weekly were less likely to report CWP compared to 
those drinking none or infrequently (Table 4, Figure 1) (0.9 vs 2.6%, OR 0.33, 0.31-0.35, aOR 0.56, 
0.53-0.61). This was observed among those of white and non-white ethnicity and in both genders. 
Causal effect of weekly alcohol consumption on risk of CWP 
The estimate of the causal effect of alcohol consumption on risk of CWP using instrumental variable 
analysis did not show a decreased risk with weekly consumption of alcohol (Table 4, Figure 1) (OR 
1.29, 0.96-1.74). Effect estimates were similar for males and females, and those of white and non-
white ethnicity, ranging from ORs of 1.28 to 1.49, apart from among non-white males which showed 
a small decreased risk of OR 0.96. None of the effect estimates excluded the null in their 99% 
confidence intervals. 
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DISCUSSION 
We did not find evidence for a protective effect of weekly alcohol consumption on the reporting of 
CWP. Those participants with a genetic predisposition to avoid alcohol were less likely to report CWP, 
not more. The results of the instrumental variable analysis suggest there could be a small harmful 
effect of alcohol on CWP. 
 
The main strength of the study is that of the Mendelian randomisation method. To the extent that 
variants of the rs1229984 SNP are distributed randomly among the population, they are not 
confounded with other factors that may have an effect on the outcome. This method also deals with 
the problem of so-called ‘reverse causation’. While in traditional observational studies the direction 
of causality between two associated variables is difficult to ascertain, in our study, it is not possible 
that being less likely to report pain caused people to carry the A allele. Additional strengths of this 
study include its large sample size, the availability of a number of other CWP risk markers, and similar 
levels of alcohol consumption as found in other surveys in the UK population [6]. Also, the definition 
of CWP used (chronic pain all over the body that has interfered with activities and experienced for 
more than 3 months) gave prevalence estimates consistent with that of fibromyalgia, indicating that 
we were likely considering a phenotype at the same extreme end of the pain spectrum. 
 
There are however limitations to our study. One is that rare variants of the SNP may not be randomly 
distributed throughout the population. Carriers of the rs1229984 A allele are more likely to be of non-
white ethnicity. In the sample studied here, ethnicity is itself associated with socio-demographic 
factors, and with the reporting of pain [16]. However, the observed associations between the SNP 
variant and CWP held when looking at those of self-reported white ethnic background alone. 
Furthermore, for our analysis all those of non-white ethnic background were included in the same 
category. This was not in order to make any inferences about this group of people, as we would expect 
it to be quite heterogeneous, but only included for completeness. Another limitation of the method is 
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that the SNP used may have pleiotropic effects, that is, effects of the variants on CWP other than 
through their effects on alcohol consumption. In our instrumental variable analysis we dealt with this 
by adjusting for a number of common risk markers for CWP. This however makes the assumption that 
these risk markers were not on the casual pathway between alcohol consumption and CWP. For some 
of these covariates, for example gender and ethnicity, this was a reasonable assumption. It is possible 
however, that some of these covariates are pathway variables mediating the effect of alcohol on CWP 
in which case our estimate of the effect could be biased [5]. The direction of this potential bias could 
mean we have underestimated the effect of alcohol on pain so would not alter the conclusion that 
alcohol does not have a positive effect on pain. 
 
Previous studies have found that CWP reporting was greater in non-drinkers compared to those 
drinking alcohol moderately [3,15], and the current study confirmed that association. The current 
study also concluded that, using variants of SNPs as a marker for alcohol consumption, alcohol 
consumption does not prevent CWP. While previous studies were observational and could only make 
a comment about associations between alcohol consumption and CWP, the current study used a 
method that allows an estimate of the causal effect of alcohol on CWP. We can conclude that the 
previous results were not due to moderate alcohol consumption causing people to have less pain. The 
results of those observational studies could instead be due to the effect of having pain on alcohol 
consumption, that is, people with pain being more likely to reduce their consumption. Our study did 
not have the power to examine small effects of alcohol consumption on CWP, and we cannot rule out 
the null hypothesis that there was no effect. However, the direction of effect means it is possible that 
alcohol consumption has a small harmful effect on CWP. It may be that at the population level, people 
with CWP reduce their consumption of alcohol because of the harmful effect on their symptoms. 
 
In this study, the best estimate of the effect of weekly alcohol consumption on risk of CWP was small 
(risk ratio of about 1.3). For a condition with a low prevalence (1.5%), this represents an absolute 
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increase in risk of about 4 people per thousand. A randomised trial designed to assess this size of 
difference at 5% significance level with 90% power, and 100% treatment compliance, would require a 
sample size of over 67,000 participants.  However, this estimate effect of alcohol on CWP has been 
adjusted for covariates. Some of these are among possible consequences of drinking alcohol (higher 
BMI, worse mood, lower levels of education) and could be regarded as potential mediators of its 
influence on CWP. In that case, it is possible that the true effect is larger than this. It is also possible 
that these covariates are colliders, consequences of both alcohol consumption and CWP, which would 
also influence the estimate of effect. 
 
This results of this and previous studies leave some unanswered questions. Here, we estimated a small 
negative effect of alcohol consumption on CWP but could not rule out sampling error. If drinking 
alcohol does increase the risk of CWP we would have to consider by what mechanism. A general 
question for epidemiological researchers is how such a strong relationship as seen in the population 
between moderate levels of alcohol consumption and decreased CWP might come about given that 
that alcohol consumption does not lower the risk of CWP. The population-level effect may be 
behavioural, that is to say people who are at higher risk of CWP actively change their behaviour to 
avoid drinking. Possible reasons for avoidance of alcohol among patients with CWP are the use of 
medications for which alcohol consumption is proscribed, or that alcohol may be exacerbating 
symptoms, but this is an area for future research. 
 
In conclusion, this study found those participants that had a genetic predisposition to avoid alcohol 
consumption reported less CWP not more. An instrumental variable analysis showed that weekly 
alcohol consumption does not cause the risk of CWP to be decreased. The interpretation of 
observational population studies as showing a protective effective of alcohol against pain is not 
supported. 
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Table 1 Participant characteristics by genotype 
 AA/AG GG OR (99% CI) Difference (99% CI) n 
      
Age, mean (SD), years 56.1 (8.16) 56.6 (8.09) - 0.44 (0.32-0.57) 486,306 
      
Gender, Female (%) 15,412 (54.1) 248,218 (54.2) 1.01 (0.98-1.04) - 486,306 
      
Ethnicity, Non-white (%) 4,464 (15.6) 21,190 (4.7) 0.26 (0.25-0.27) - 484,007 
      
BMI, mean (SD) 27.0 (4.64) 27.4 (4.80) - 0.48 (0.40-0.55) 484,335 
      
Townsend Index, mean (SD) -1.16 (3.175) -1.32 (3.083) - -0.16 (-0.21- -0.11) 485,708 
      
Employment 
status 
Employed or self-employed 16,767 (59.4) 261,454 (57.4) 1 [Ref] - 
483,819 
Retired 8.703 (30.8) 153,272 (33.6) 1.13 (1.09-1.17) - 
Unable to work 801 (2.8) 15,223 (3.3) 1.22 (1.11-1.34) - 
Unemployed 548 (1.9) 7,406 (1.6) 0.87 (0.77-0.97) - 
None of above 1425 (5.1) 18.220 (4.0) 0.82 (0.76-0.88) - 
      
Smoking 
Never 11,547 (40.8) 182,851 (40.1) 1 [Ref] - 
483,805 
Tried once or twice 4,175 (14.8) 66,273 (14.6) 1.00 (0.96-1.05) - 
Previous, occasional 3,230 (11.4) 52,223 (11.5) 1.02 (0.97-1.08) - 
Previous, most days 6,389 (22.6) 106,055 (23.3) 1.05 (1.00-1.09) - 
Current, occasionally 857 (3.0) 12,373 (2.7) 0.91 (0.83-1.00) - 
Current, most days 2,098 (7.4) 35,734 (7.8) 1.08 (1.01-1.15) - 
      
University degree, Yes (%) 10,836 (38.7) 146,423 (32.4) 0.76 (0.73-0.78) - 480,062 
      
Miserable, Yes (%) 11,570 (41.7) 192,214, (42.8) 1.05 (1.02-1.08) - 476,645 
      
Fed up, Yes (%) 10,711 (38.81) 181,903 (40.7) 1.08 (1.05-1.12) - 474,587 
      
Frequent family/friend visits, Yes (%) 11,243 (40.0) 193,367 (42.6) 1.11 (1.08-1.15) - 482,210 
      
OR, odds ratio or multinomial odds ratio; CI, confidence interval; n, number of participants used for calculation; BMI, body mass index 
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Table 2 Association of CWP with variants of rs1229984 
Ethnicity Gender Variant No CWP CWP OR (99% CI) n AOR (99% CI) n 
         
All 
All 
AA/AG 27973 (98.8) 344 (1.2) 1 [Ref] 
484,575 
1 [Ref] 
454,400 
GG 449807 (98.6) 6451 (1.4) 1.17 (1.01-1.35) 1.14 (0.97-1.33) 
        
Male 
AA/AG 12876 (99.0) 125 (1.0) 1 [Ref] 
221,873 
1 [Ref] 
207,436 
GG 206517 (98.9) 2355 (1.1) 1.17 (0.93-1.49) 1.11 (0.86-1.44) 
        
Female 
AA/AG 15097 (98.6) 219 (1.4) 1 [Ref] 
262,702 
1 [Ref] 
246,964 
GG 243290 (98.3) 4096 (1.7) 1.16 (0.97-1.39) 1.15 (0.95-1.40) 
         
White 
All 
AA/AG 23511 (98.9) 250 (1.1) 1 [Ref] 
457,553 
1 [Ref] 
432,962 
GG 428084 (98.7) 5708 (1.3) 1.25 (1.06-1.48) 1.14 (0.95-1.36) 
        
Male 
AA/AG 11009 (99.2) 90 (0.8) 1 [Ref] 
209,237 
1 [Ref] 
197,702 
GG 196027 (98.9) 2111 (1.1) 1.32 (1.00-1.74) 1.14 (0.85-1.54) 
        
Female 
AA/AG 12502 (98.7) 160 (1.3) 1 [Ref] 
248,316 
1 [Ref] 
235,260 
GG 232057 (98.5) 3597 (1.5) 1.21 (0.98-1.49) 1.14 (0.91-1.42) 
         
Non-white 
All 
AA/AG 4317 (97.9) 92 (2.1) 1 [Ref] 
25,390 
1 [Ref] 
21,438 
GG 20269 (96.6) 712 (3.4) 1.65 (1.24-2.20) 1.16 (0.84-1.61) 
        
Male 
AA/AG 1801 (98.2) 34 (1.9) 1 [Ref] 
11,713 
1 [Ref] 
9,734 
GG 9648 (97.7) 230 (2.3) 1.26 (0.78-2.04) 0.99 (0.56-1.74) 
        
Female 
AA/AG 2516 (97.7) 58 (2.3) 1 [Ref] 
13,677 
1 [Ref] 
11,704 
GG 10621 (95.7) 482 (4.3) 1.97 (1.37-2.83) 1.23 (0.82-1.85) 
         
CWP, chronic widespread pain; OR, odds ratio; CI, confidence interval; n, number of participants used for individual calculation; AOR, 
adjusted odds ratio 
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Table 3 Association of alcohol consumption with variants of rs1229984 
Ethnicity Gender Variant Non or infrequent Weekly consumption OR (99% CI) n AOR (99% CI) n 
         
All 
All 
AA/AG 12304 (43.3) 16097 (56.7) 1 [Ref] 
485,227 
1 [Ref] 
454,758 
GG 138480 (30.3) 318346 (69.7) 1.76 (1.70-1.81) 1.69 (1.63-1.76) 
        
Male 
AA/AG 4290 (32.9) 8753 (67.1) 1 [Ref] 
222,143 
1 [Ref] 
207,549 
GG 46519 (22.3) 162581 (77.8) 1.71 (1.63-1.80) 1.60 (1.52-1.69) 
        
Female 
AA/AG 8014 (52.2) 7344 (47.8) 1 [Ref] 
263,084 
1 [Ref] 
247,209 
GG 91961 (37.1) 155765 (62.9) 1.85 (1.77-1.93) 1.77 (1.69-1.86) 
         
White 
All 
AA/AG 9031 (38.0) 14762 (62.0) 1 [Ref] 
458,029 
1 [Ref] 
433,273 
GG 124252 (28.6) 309984 (71.4) 1.53 (1.47-1.58) 1.69 (1.63-1.76) 
        
Male 
AA/AG 3087 (27.8) 8029 (72.2) 1 [Ref] 
209,414 
1 [Ref] 
197,798 
GG 40760 (20.6) 157538 (79.4) 1.49 (1.40-1.57) 1.60 (1.51-1.70) 
        
Female 
AA/AG 5944 (46.9) 6733 (53.1) 1 [Ref] 
248,615 
1 [Ref] 
235,475 
GG 83492 (35.4) 152446 (64.6) 1.61 (1.53-1.69) 1.76 (1.68-1.85) 
         
Non-white 
All 
AA/AG 3189 (71.6) 1265 (28.4) 1 [Ref] 
25,533 
1 [Ref] 
21,485 
GG 13614 (64.6) 7465 (35.4) 1.38 (1.26-1.52) 1.65 (1.48-1.84) 
        
Male 
AA/AG 1171 (63.1) 685 (36.9) 1 [Ref] 
11,786 
1 [Ref] 
9,751 
GG 5456 (54.9) 4474 (45.1) 1.40 (1.22-1.60) 1.61 (1.38-1.88) 
        
Female 
AA/AG 2018 (77.7) 580 (22.3) 1 [Ref] 
13,747 
1 [Ref] 
11,734 
GG 8158 (73.2) 2991 (26.8) 1.28 (1.11-1.46) 1.70 (1.45-1.98) 
         
OR, odds ratio; CI, confidence interval; n, number of participants used for individual calculation; AOR, adjusted odds ratio 
 
  
21 
 
Table 4 Association of weekly alcohol consumption and CWP, and causal effect of weekly consumption on CWP 
 
      Association in the population Estimated causal effect 
Ethnicity Gender Consumption No CWP CWP OR (99% CI) n AOR (99% CI) n OR (99% CI) n 
           
All 
All 
None 151739 (97.4) 4077 (2.6) 1 [Ref] 
499,988 
1 [Ref] 
465,150 
1 [Ref] 
454,178 
Weekly 341132 (99.1) 3040 (0.9) 0.33 (0.31-0.35) 0.56 (0.53-0.61) 1.29 (0.96-1.74) 
          
Male 
None 51048 (97.8) 1150 (2.2) 1 [Ref] 
227,901 
1 [Ref] 
211,352 
1 [Ref] 
207,324 
Weekly 174272 (99.2) 1431 (0.8) 0.36 (0.33-0.40) 0.61 (0.54-0.69) 1.28 (0.73-2.23) 
          
Female 
None 100691 (97.2) 2927 (2.8) 1 [Ref] 
272,087 
1 [Ref] 
253,798 
1 [Ref] 
262,507 
Weekly 166860 (99.0) 1609 (1.0) 0.33 (0.31-0.36) 0.54 (0.49-0.59) 1.29 (0.91-1.82) 
           
White 
All 
None 134234 (97.6) 3327 (2.4) 1 [Ref] 
471,633 
1 [Ref] 
442,840 
1 [Ref] 
432,779 
Weekly 331181 (99.1) 2891 (0.9) 0.35 (0.33-0.38) 0.57 (0.53-0.62) 1.31 (0.93-1.84) 
          
Male 
None 44106 (98.0) 923 (2.0) 1 [Ref] 
214,785 
1 [Ref] 
201,349 
1 [Ref] 
197,612 
Weekly 168396 (99.2) 1360 (0.8) 0.39 (0.35-0.43) 0.63 (0.55-0.71) 1.37 (0.73-2.57) 
          
Female 
None 90128 (97.4) 2404 (2.6) 1 [Ref] 
256,848 
1 [Ref] 
241,491 
1 [Ref] 
235,167 
Weekly 162785 (99.1) 1531 (0.9) 0.35 (0.32-0.38) 0.54 (0.49-0.59) 1.28 (0.86-1.89) 
           
Non-
white 
All 
None 16828 (95.9) 721 (4.1) 1 [Ref] 
26,657 
1 [Ref] 
22,310 
1 [Ref] 
21,399 
Weekly 8968 (98.5) 140 (1.5) 0.36 (0.29-0.46) 0.52 (0.39-0.68) 1.35 (0.69-2.63) 
          
Male 
None 6617 (96.9) 214 (3.1) 1 [Ref] 
12,155 
1 [Ref] 
10,003 
1 [Ref] 
9,712 
Weekly 5257 (98.7) 67 (1.3) 0.39 (0.27-0.57) 0.49 (0.32-0.75) 0.96 (0.30-3.13) 
          
Female 
None 10211 (95.3) 507 (4.7) 1 [Ref] 
14,502 
1 [Ref] 
12,307 
1 [Ref] 
11,687 
Weekly 3711 (98.1) 73 (1.9) 0.40 (0.29-0.55) 0.52 (0.36-0.75) 1.49 (0.68-3.28) 
           
CWP, chronic widespread pain; OR, odds ratio; CI, confidence interval; n, number of participants used for individual calculation; AOR, adjusted odds ratio 
